Lirafugratinib

DRUG2 trials

Sponsors

Elevar Therapeutics Inc., Elevar Therapeutics

Conditions

FGFR2 Gene Fusion/RearrangementLocally Advanced or Metastatic Solid Tumors (Excluding Cholangiocarcinoma) With FGFR2 Fusion or RearrangementOther Solid Tumors, AdultPreviously TreatedUnresectable

Phase 2

A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement

RecruitingNCT07359820

Elevar TherapeuticsFGFR2 Gene Fusion/Rearrangement, Other Solid Tumors, Adult

Start: 2026-06-04End: 2028-12-01Target: 30Updated: 2026-09-03

A Phase 2, Open-Label, Single-Arm Study of Lirafugratinib in Patients With Previously Treated, Unresectable, Locally Advanced or Metastatic Solid Tumors (Excluding Cholangiocarcinoma) With FGFR2 Fusion or Rearrangement

Not yet recruitingCTIS2025-523923-22-00

Elevar Therapeutics Inc.Locally Advanced or Metastatic Solid Tumors (Excluding Cholangiocarcinoma) With FGFR2 Fusion or Rearrangement, Previously Treated, Unresectable

Target: 14Updated: 2026-07-10

Related Papers

A phase 2, open-label, single-arm study of lirafugratinib in patients with previously treated, unresectable, locally advanced, or metastatic solid tumors (excluding cholangiocarcinoma) with <i>FGFR2</i> fusion or rearrangement.

Journal of Clinical Oncology2026-05-28